| __timestamp | Catalent, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1229100000 | 9335772 |
| Thursday, January 1, 2015 | 1215500000 | 999000 |
| Friday, January 1, 2016 | 1260500000 | 978000 |
| Sunday, January 1, 2017 | 1420800000 | 952000 |
| Monday, January 1, 2018 | 1710800000 | 956000 |
| Tuesday, January 1, 2019 | 1712900000 | 8122999 |
| Wednesday, January 1, 2020 | 2111000000 | 8712000 |
| Friday, January 1, 2021 | 2646000000 | 13980000 |
| Saturday, January 1, 2022 | 3188000000 | 21135000 |
| Sunday, January 1, 2023 | 3216000000 | 10755000 |
| Monday, January 1, 2024 | 3428000000 |
In pursuit of knowledge
In the dynamic world of biotechnology and pharmaceuticals, understanding cost structures is crucial. Catalent, Inc. and Iovance Biotherapeutics, Inc. offer a fascinating comparison. Over the past decade, Catalent's cost of revenue has surged by approximately 179%, from $1.2 billion in 2014 to an impressive $3.4 billion in 2024. This growth reflects Catalent's expanding operations and increased production capabilities.
In contrast, Iovance Biotherapeutics, Inc. presents a different narrative. Starting with a modest cost of revenue of around $933,000 in 2014, it peaked at $21 million in 2022, before dropping to $10.8 million in 2023. This fluctuation highlights the challenges faced by smaller biotech firms in scaling operations.
The data underscores the diverse financial landscapes within the industry, with Catalent's consistent growth contrasting sharply with Iovance's more volatile trajectory.
Cost of Revenue: Key Insights for Amgen Inc. and Catalent, Inc.
Comparing Cost of Revenue Efficiency: United Therapeutics Corporation vs Catalent, Inc.
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Catalent, Inc.
Cost Insights: Breaking Down Catalent, Inc. and Xenon Pharmaceuticals Inc.'s Expenses
Cost of Revenue: Key Insights for Catalent, Inc. and Celldex Therapeutics, Inc.
Cost of Revenue Comparison: Catalent, Inc. vs Travere Therapeutics, Inc.
Catalent, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Telix Pharmaceuticals Limited vs Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down Ionis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: ACADIA Pharmaceuticals Inc. and Iovance Biotherapeutics, Inc.
Cost of Revenue Trends: Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Iovance Biotherapeutics, Inc. vs Travere Therapeutics, Inc.